○Shuntaro Shimizu1, Tomoya Hayashi1,2,3, Koji Sakamoto4, Naozumi Hashimoto5, Kouji Kobiyama1,2,3, Hideo Negishi1,2, Brucu Temizoz1,2,3, Cevayir Coban2,6, Ken J Ishii1,2,3
(1.Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT), Tokyo, Japan, 2.International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo (IMSUT), Tokyo, Japan, 3.Laboratory of Adjuvant Innovation, Center for Vaccine and Adjuvant Research (CVAR), National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan, 4.Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan, 5.Department of Respiratory Medicine, Fujita Health University, Nagoya, Japan, 6.Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT), Tokyo, Japan)
Abstract password authentication.
Please enter password to access the abstracts.
The Secretariat will inform registered participants by e-mail on August 28. <tentative>